World Journal of Hepatology - Baishideng Publishing Group

Advanced Search

BPG is committed to discovery and dissemination of knowledge

JOURNAL HOME

Number of total visits: 2816118

Number of visits today: 172

Number of downloads: 2065786

MEMBERSHIP

BPG JOURNALS

Cited by in F6Publishing

For:	Wang YX, Lin C, Cui LJ, Deng TZ, Li QM, Chen FY, Miao XP. Mechanism of M2 macrophage-derived extracellular vesicles carrying lncRNA MEG3 in inflammatory responses in ulcerative colitis. Bioengineered 2021;12:12722-39. [PMID: 34895044 DOI: 10.1080/21655979.2021.2010368] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]

For:

Wang YX, Lin C, Cui LJ, Deng TZ, Li QM, Chen FY, Miao XP. Mechanism of M2 macrophage-derived extracellular vesicles carrying lncRNA MEG3 in inflammatory responses in ulcerative colitis. Bioengineered 2021;12:12722-39. [PMID: 34895044 DOI: 10.1080/21655979.2021.2010368] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]

Number	Citing Articles
1	Guo W, Su L, Zhang H, Mi Z. Role of M2 macrophages-derived extracellular vesicles in IL-1β-stimulated chondrocyte proliferation and inflammatory responses. Cell Tissue Bank 2023;24:93-107. [PMID: 35687263 DOI: 10.1007/s10561-022-10016-6] [Reference Citation Analysis]
2	Innocenti T, Bigagli E, Lynch EN, Galli A, Dragoni G. MiRNA-Based Therapies for the Treatment of Inflammatory Bowel Disease: What Are We Still Missing? Inflamm Bowel Dis 2023;29:308-23. [PMID: 35749310 DOI: 10.1093/ibd/izac122] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3	Wang C, Xu M, Fan Q, Li C, Zhou X. Therapeutic potential of exosome-based personalized delivery platform in chronic inflammatory diseases. Asian J Pharm Sci 2023;18:100772. [PMID: 36896446 DOI: 10.1016/j.ajps.2022.100772] [Reference Citation Analysis]
4	Xu J, Wang X, Zhu C, Wang K. A review of current evidence about lncRNA MEG3: A tumor suppressor in multiple cancers. Front Cell Dev Biol 2022;10:997633. [PMID: 36544907 DOI: 10.3389/fcell.2022.997633] [Reference Citation Analysis]
5	Li Z, Gao J, Sun D, Jiao Q, Ma J, Cui W, Lou Y, Xu F, Li S, Li H. LncRNA MEG3: Potential stock for precision treatment of cardiovascular diseases. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.1045501] [Reference Citation Analysis]
6	Ni S, Liu Y, Zhong J, Shen Y. Inhibition of LncRNA-NEAT1 alleviates intestinal epithelial cells (IECs) dysfunction in ulcerative colitis by maintaining the homeostasis of the glucose metabolism through the miR-410-3p-LDHA axis. Bioengineered 2022;13:8961-71. [DOI: 10.1080/21655979.2022.2037957] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]